Evidence map›Paper›PMID 28470594›Full record

ArticlePharmacoEconomics2017

How to Appropriately Extrapolate Costs and Utilities in Cost-Effectiveness Analysis.

Laura Bojke, Andrea Manca, Miqdad Asaria, Ronan Mahon, Shijie Ren, Stephen Palmer

Abstract read
PubMed Publisher
In one paragraph

Article in PharmacoEconomics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Friedreich's ataxia patient pathway in Europe.Frontiers in health services · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Article
  13. Article
  14. Article
  15. The Burden, Future Trends, And Economic Impact Of Lung Cancer In Saudi Arabia.ClinicoEconomics and outcomes research : CEOR · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Laura BojkeCentre for Health Economics, University of York, Heslington, York, yo10 5dd, UK. laura.bojke@york.ac.uk.ORCID http://orcid.org/0000-0001-7921-9109
Andrea MancaCentre for Health Economics, University of York, Heslington, York, yo10 5dd, UK.
Miqdad AsariaCentre for Health Economics, University of York, Heslington, York, yo10 5dd, UK.
Ronan MahonCentre for Health Economics, University of York, Heslington, York, yo10 5dd, UK.
Shijie RenUniversity of Sheffield, Sheffield, UK.
Stephen PalmerCentre for Health Economics, University of York, Heslington, York, yo10 5dd, UK.

Funding

Department of Health CDF-2009-02-21
6 · The paper itself

Abstract

Costs and utilities are key inputs into any cost-effectiveness analysis. Their estimates are typically derived from individual patient-level data collected as part of clinical studies the follow-up duration of which is often too short to allow a robust quantification of the likely costs and benefits a technology will yield over the patient's entire lifetime. In the absence of long-term data, some form of temporal extrapolation-to project short-term evidence over a longer time horizon-is required. Temporal extrapolation inevitably involves assumptions regarding the behaviour of the quantities of interest beyond the time horizon supported by the clinical evidence. Unfortunately, the implications for decisions made on the basis of evidence derived following this practice and the degree of uncertainty surrounding the validity of any assumptions made are often not fully appreciated. The issue is compounded by the absence of methodological guidance concerning the extrapolation of non-time-to-event outcomes such as costs and utilities. This paper considers current approaches to predict long-term costs and utilities, highlights some of the challenges with the existing methods, and provides recommendations for future applications. It finds that, typically, economic evaluation models employ a simplistic approach to temporal extrapolation of costs and utilities. For instance, their parameters (e.g. mean) are typically assumed to be homogeneous with respect to both time and patients' characteristics. Furthermore, costs and utilities have often been modelled to follow the dynamics of the associated time-to-event outcomes. However, cost and utility estimates may be more nuanced, and it is important to ensure extrapolation is carried out appropriately for these parameters.

Indexed as

Models, EconomicBiomedical TechnologyCost-Benefit AnalysisDecision MakingHumansQuality-Adjusted Life YearsTechnology Assessment, BiomedicalTime FactorsUncertaintyBaseline UtilityDecision UncertaintyHealth Assessment Questionnaire ScoreIndividual Patient DataPsoriasis Area Severity Index

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.